JP2019523633A - 組織の損傷に関連した疾患及び障害を予防及び治療する組織保護ペプチド - Google Patents

組織の損傷に関連した疾患及び障害を予防及び治療する組織保護ペプチド Download PDF

Info

Publication number
JP2019523633A
JP2019523633A JP2018556357A JP2018556357A JP2019523633A JP 2019523633 A JP2019523633 A JP 2019523633A JP 2018556357 A JP2018556357 A JP 2018556357A JP 2018556357 A JP2018556357 A JP 2018556357A JP 2019523633 A JP2019523633 A JP 2019523633A
Authority
JP
Japan
Prior art keywords
cancer
disease
peptide
peptides
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018556357A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019523633A5 (enExample
Inventor
ブリネス マイケル
ブリネス マイケル
セラミ アンソニイ
セラミ アンソニイ
Original Assignee
アライム ファーマシューティカルズ，インコーポレーテッド
アライム ファーマシューティカルズ，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アライム ファーマシューティカルズ，インコーポレーテッド, アライム ファーマシューティカルズ，インコーポレーテッド filed Critical アライム ファーマシューティカルズ，インコーポレーテッド
Publication of JP2019523633A publication Critical patent/JP2019523633A/ja
Publication of JP2019523633A5 publication Critical patent/JP2019523633A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2018556357A 2016-04-29 2017-04-28 組織の損傷に関連した疾患及び障害を予防及び治療する組織保護ペプチド Pending JP2019523633A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662329743P 2016-04-29 2016-04-29
US62/329,743 2016-04-29
PCT/US2017/030100 WO2017189988A1 (en) 2016-04-29 2017-04-28 Tissue protective peptides for preventing and treating diseases and disorders associated with tissue damage

Publications (2)

Publication Number Publication Date
JP2019523633A true JP2019523633A (ja) 2019-08-29
JP2019523633A5 JP2019523633A5 (enExample) 2020-06-18

Family

ID=60161215

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018556357A Pending JP2019523633A (ja) 2016-04-29 2017-04-28 組織の損傷に関連した疾患及び障害を予防及び治療する組織保護ペプチド

Country Status (5)

Country Link
US (1) US10864253B2 (enExample)
EP (1) EP3448415A4 (enExample)
JP (1) JP2019523633A (enExample)
CN (1) CN109310741A (enExample)
WO (1) WO2017189988A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3946547A4 (en) * 2019-03-26 2023-01-18 Pocket Naloxone Corp. DEVICES AND METHODS FOR DELIVERING PHARMACEUTICAL COMPOSITIONS
KR20220009954A (ko) * 2019-04-17 2022-01-25 컴퍼스 패쓰파인더 리미티드 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법
CN120131531A (zh) * 2019-12-13 2025-06-13 麻省理工学院 作为上皮层疗法的聚合物的组织催化生长

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11508899A (ja) * 1995-07-05 1999-08-03 イエダ リサーチ アンド デベロプメント カンパニイ リミテッド Ｔ細胞介在の病気を治療するための製剤と方法
US20070060519A1 (en) * 2004-01-28 2007-03-15 Johannes Rozing Hsp therapy in conjunction with a low antigenicity diet
US20090202618A1 (en) * 2003-11-24 2009-08-13 Yeda Research & Development Co. Ltd Dna vaccines encoding hsp60 peptide fragments for treating autoimmune diseases
US20110212105A1 (en) * 2006-04-28 2011-09-01 Vivian Huerta Galindo Method to block the infection by flaviviruses, molecules and uses
CA2940078A1 (en) * 2014-03-03 2015-09-11 Centro De Ingenieria Genetica Y Biotecnologia Beta hairpin peptides having anti-viral properties against the dengue virus

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1479268A (en) 1973-07-05 1977-07-13 Beecham Group Ltd Pharmaceutical compositions
CH596313A5 (enExample) 1975-05-30 1978-03-15 Battelle Memorial Institute
US4414147A (en) 1981-04-17 1983-11-08 Massachusetts Institute Of Technology Methods of decreasing the hydrophobicity of fibroblast and other interferons
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US5051448A (en) 1984-07-24 1991-09-24 The Mclean Hospital Corporation GABA esters and GABA analog esters
EP0229108B1 (en) 1985-06-26 1990-12-27 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
WO1994005332A2 (en) 1992-09-01 1994-03-17 Berlex Laboratories, Inc. Glycolation of glycosylated macromolecules
US5559103A (en) 1993-07-21 1996-09-24 Cytel Corporation Bivalent sialyl X saccharides
US5576423A (en) 1994-12-02 1996-11-19 Schering Corporation Antibodies to the slam protein expressed on activated T cells
IL114407A0 (en) * 1995-06-30 1995-10-31 Yeda Res & Dev Novel peptides and pharmaceutical compositions comprising them
PA8536201A1 (es) 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
EP1519957B1 (en) * 2002-07-03 2009-03-04 Fondazione Centro San Raffaele Del Monte Tabor Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair
MXPA05002617A (es) 2002-09-09 2005-09-08 Warren Pharmaceuticals Inc Eritropoyetinas de accion prolongada que mantienen la actividad protectora de tejidos de la eritropoyetina endogena.
WO2005025606A1 (en) 2003-09-09 2005-03-24 Warren Pharmaceuticals, Inc. Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
ZA200603396B (en) 2003-09-29 2007-11-28 Warren Pharmaceuticals Inc Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
EP1768698A4 (en) * 2004-06-17 2009-01-28 Medimmune Inc IMMUNOGENIC COMPOSITIONS COMPRISING HMGB1 POLYPEPTIDES
ZA200706016B (en) * 2004-12-21 2008-12-31 Musc Found For Res Dev Compositions and methods for promoting wound healing and tissue regeneration
AU2006206647C1 (en) * 2005-01-19 2011-01-20 Vaxinnate Corporation Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response
CA2982909A1 (en) 2005-08-05 2007-02-15 Araim Pharmaceuticals, Inc. Tissue protective peptides and uses thereof
CN104689298A (zh) * 2008-01-22 2015-06-10 阿拉伊姆药品公司 用于预防和治疗组织损伤相关疾病和病症的组织保护肽和肽类似物
CN107188948B (zh) 2011-04-26 2021-11-30 斯特姆里姆有限公司 用于诱导组织再生的肽及其应用
US9561274B2 (en) 2011-06-07 2017-02-07 University Of Hawaii Treatment and prevention of cancer with HMGB1 antagonists
US9046530B2 (en) * 2011-12-02 2015-06-02 Board Of Regents, The University Of Texas System Methods and compositions for chlamydial antigens as reagents for diagnosis of tubal factor infertility and chlamydial infection
CA2918223A1 (en) * 2013-07-17 2015-01-22 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
US9840555B2 (en) * 2013-11-04 2017-12-12 Li-Te Chin Method for producing human monoclonal antibodies that binds to at least one part of HMGB1

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11508899A (ja) * 1995-07-05 1999-08-03 イエダ リサーチ アンド デベロプメント カンパニイ リミテッド Ｔ細胞介在の病気を治療するための製剤と方法
US20090202618A1 (en) * 2003-11-24 2009-08-13 Yeda Research & Development Co. Ltd Dna vaccines encoding hsp60 peptide fragments for treating autoimmune diseases
US20070060519A1 (en) * 2004-01-28 2007-03-15 Johannes Rozing Hsp therapy in conjunction with a low antigenicity diet
US20110212105A1 (en) * 2006-04-28 2011-09-01 Vivian Huerta Galindo Method to block the infection by flaviviruses, molecules and uses
CA2940078A1 (en) * 2014-03-03 2015-09-11 Centro De Ingenieria Genetica Y Biotecnologia Beta hairpin peptides having anti-viral properties against the dengue virus

Also Published As

Publication number Publication date
US20190134156A1 (en) 2019-05-09
EP3448415A1 (en) 2019-03-06
EP3448415A4 (en) 2019-11-06
WO2017189988A8 (en) 2018-01-25
US10864253B2 (en) 2020-12-15
CN109310741A (zh) 2019-02-05
WO2017189988A1 (en) 2017-11-02

Similar Documents

Publication Publication Date Title
JP5542064B2 (ja) 組織の損傷に関連した疾患及び障害を予防及び治療する、組織保護ペプチド及びペプチド類似体
JP6479789B2 (ja) 組織の損傷に関連した疾患及び障害を予防及び治療する、組織保護ペプチド及びペプチド類似体
JP2019523633A (ja) 組織の損傷に関連した疾患及び障害を予防及び治療する組織保護ペプチド
AU2016203452B2 (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200420

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200420

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210427

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211116